Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Trials)

American Journal of Cardiology

Volumn 100, Issue 7, 2007, Pages 1047-1051

  Murphy, Sabina A ^a   Cannon, Christopher P ^a   Wiviott, Stephen D ^a   de Lemos, James A ^b   Blazing, Michael A ^c   McCabe, Carolyn H ^a   Califf, Robert M ^c   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; TYROSINE;

EID: 34548697581     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.04.053     Document Type: Article

References (12)

1. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
3. Wiviott S.D., de Lemos J.A., Cannon C.P., Blazing M., Murphy S.A., McCabe C.H., Califf R., and Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113 (2006) 1406-1414
4. Blazing M.A., De Lemos J.A., Dyke C.K., Califf R.M., Bilheimer D., and Braunwald E. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 142 (2001) 211-217
5. Cannon C.P., McCabe C.H., Belder R., Breen J., and Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 89 (2002) 860-861
6. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
7. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
8. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rutks I., Ho M., Larsen G., McCall A., Pineros S., and Sales A. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 (2004) 1427 1236
9. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
10. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
11. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease-is it time to shift our goals?. N Engl J Med 352 (2005) 1483-1484
12. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28